Media Report
Angel pharmaceutical R&D center officially launched.New progress made in the 10 billion biomedical projects of Jiaxing Science and Technology Zone.
Reading Jia Nanhu 07-22 11:18
Angel pharmaceutical R&D center officially launched. New progress made in the 10 billion biomedical projects of Jiaxing Science and Technology zone. On the morning of yesterday, the Opening ceremony of Angel pharmaceuticals R&D center was held in Zhejiang Institute of future technology (Jiaxing). As an important part of the 10 billion biomedical projects signed in Jiaxing Science and Technology Zone, the official opening of the pharmaceutical R&D center also marks the new progress of the 10 billion biomedical project in Jiaxing Science and Technology Zone. Shao Panfeng, deputy secretary and chief of Nanhu District Committee, director of Jiaxing Science and Technology City Management Committee, and Shen Jinhua, deputy director of Nanhu District, attended the event.
Last year, the R&D and industrialization project of innovative drugs with a total investment of 1.5 billion US dollars was settled in Jiaxing Science and Technology Zone in the form of "cloud contract". Since then, the pharmaceutical industry has been registered and developed rapidly.
It is reported that the R&D center of Jiaxing headquarters of Angel Pharmaceutical Co., Ltd., more than 3000 square meters, has complete biological and chemical innovative drug research and development laboratory and complete drug analysis equipment. Today, the Sino US dual R&D center, in the Jiaxing headquarters and San Francisco USA, have been launched, attracting a number of senior professionals in the industry to join in, building a team of early research and development, clinical development and drug manufacturing of innovative drugs across the United States and China. What is more gratifying is that Angel pharmaceutical has established a comprehensive cooperative relationship with top domestic medical institutions such as Peking University Cancer Hospital and Shanghai Oriental Hospital in translational medicine and clinical research, thus rapidly promoting the clinical development process of pipeline drugs in China.
Professor Richard Miller, chairman and CEO of Angel pharmaceutical
Dr. Ted Wang, general manager of Angel pharmaceutical
On the same day, Dr. Richard Miller, chairman and CEO of Angel Pharmaceutical Co., Ltd., and Dr. Ted Wang, general manager, etc. participated in the opening of the R&D center of Angel pharmaceutical online. In the view of Dr. Charles Li, Vice President of Angel pharmaceutical, China's innovative drugs are booming. The new R&D center in Jiaxing Science and Technology Zone has realized the effective allocation of innovation resources, which is conducive to accelerating the progress of new drug development and listing and seizing the global pharmaceutical industry market.
Angel pharmaceutical industry will focus on major public health drug demand areas such as cancer and autoimmune. CPI-818, the world's first ITK inhibitor for T-cell lymphoma, submitted a clinical approval application to the drug examination center of the State Food and Drug Administration in July this year. It is expected that patients will be enrolled in this year and will join the global phase II clinical trial in the future.
Shao Panfeng, deputy secretary and chief of Nanhu District Committee and director of Jiaxing Science and Technology City Management Committee
Shao Panfeng, deputy secretary and chief of Nanhu District Committee and director of Jiaxing Science and Technology City Management Committee, said that Hexi pharmaceutical industry relies on Corvus pharmaceuticals, a NASDAQ listed company The mature biopharmaceutical technology advantages of CRVs, as well as the strong strength of Betta fund, Tigermed, Hisun Pharmaceuticals and Puissance Capital Management, will be built into a leading benchmarking enterprise in the field of biomedicine in Jiaxing City, the Yangtze River Delta and even the world. At the same time, it will promote the coordinated development of a number of upstream and downstream industries related to innovative drugs, insert new wings for the development of biomedical industry in Nanhu District, and add new vitality to the high-quality development of Nanhu District. Next, Nanhu District will further enhance service awareness, strengthen policy support, provide personalized services, expand enterprise development space, and strive to create an optimal business environment demonstration area, so that every investor can feel at ease, develop and live comfortably beside the red boat of Nanhu.
Recent years, with Jiaxing Science and technology Zone as the main platform, Nanhu District takes the biomedical industry as an important part of the "1341" modern industrial system in the whole region, and takes advantage of the location advantages of the key nodes of G60 science and technology innovation corridor, and takes the biomedical industry as a new "window" for development, opening a new chapter of high-quality development. The biomedical industrial park of Jiaxing Science and technology city has a planned area of about 5.5 square kilometers, focusing on the development of biomedical frontier industries mainly including biopharmaceuticals, medical devices and medical testing, and has been listed as one of the high-energy industrial ecological parks in Jiaxing City.
Biomedical industry has become a strategic emerging industry worthy of the name of Jiaxing Science and technology city. Two major 10 billion projects were introduced and settled in Jiaxing Science and technology city last year, and the agglomeration effect of biomedical industry accelerated. At present, Jiaxing Science and Technology Zone has 104 biomedical enterprises, and the total output value of biomedical industry reached 9.145 billion yuan last year.
During the event, Angel pharmaceutical also signed strategic cooperation agreements with Tigermed and Guanhe pharmaceutical respectively.
Reporter: Yu Yanting
Correspondent: Xiang Jie
Editor: Gao Yuwen
Editor in charge: Yang Xiujuan
